塞莱科克西布处方趋势:单一机构16个月审查
Ivo H Cerda1, Helen Jung2, Maria C Guerrero3
1Harvard Medical School, Boston, MA 02115, USA.
Journal of clinical medicine
|April 26, 2025
概括
切莱科西布 (一种COX-2选择性NSAID) 的处方在疼痛管理诊所显著增加,增长速度比其他非类固醇抗炎药 (NSAID) 更快. 这表明,由于其安全性和有效性,人们越来越倾向于使用塞莱科克西布.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 疼痛管理 疼痛管理
- 医疗保健服务研究 医疗服务研究
背景情况:
- 切莱科克西布是一种选择性COX-2抑制剂,提供疼痛缓解,与传统的NSAID相比,具有更好的胃肠道安全性.
- 了解NSAID处方趋势对于评估临床实践模式和患者护理至关重要.
研究的目的:
- 在疼痛管理环境中分析塞莱科克西布处方的时间趋势.
- 为了比较切莱科西布的处方率与其他常用的NSAIDs.
主要方法:
- 追溯分析了143个切莱科西布处方和165个其他NSAID处方.
- 在16个月的时间里 (2023年1月至2024年4月) 从三个疼痛管理医生收集的数据.
- 在四个4个月间隔分析了处方,以确定趋势.
主要成果:
- 切莱科克西布的处方从8个 (2023年1月至4月) 稳步增加到67个 (2024年1月至4月).
- 其他NSAID的处方也增加,在相同的时间间隔内从26个增加到53个.
- 塞莱科克西布处方的增长率比其他NSAID更为急剧.
结论:
- 在疼痛管理诊所观察到西莱科西布处方的显著上升趋势.
- 这一趋势可能表明,越来越多的供应商更喜欢COX-2选择性抑制剂,如celecoxib.
- 需要进一步调查,以了解这些处方模式背后的驱动因素.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
Pharmacovigilance
739
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
739
Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
Time Course of Drug Effect
1.8K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
1.8K


